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Intrinsic β-lactam resistance in Stenotrophomonas maltophilia is caused by blaL1 and/or
blaL2, a kind of metallo-β-lactamase with a broad substrate spectrum including carbapen-
ems. A rapid and sensitive molecular method for the detection of blaL1 in clinical samples
is needed to guide therapeutic treatment. In present study, we ﬁrst described a loop-
mediated isothermal ampliﬁcation (LAMP) method for the rapid detection of blaL1 in clinical
samples by using two methods including a chromogenic method using calcein/Mn2+
complex and the real-time turbidity monitoring to assess the reaction. Then dissemination
of L1-producing S. maltophilia was investigated from ICU patients in three top hospital
in Beijing, China. The results showed that both methods detected the target DNA within
60 min under isothermal conditions (65◦C). The detection limit of LAMP was 3.79 pg/μl
DNA, and its sensitivity 100-fold greater than that of conventional PCR. All 21 test strains
except for S. maltophilia were negative for blaL1, indicative of the high-speciﬁcity of
the primers for the blaL1. A total of 22 L1-positive isolates were identiﬁed for LAMP-
based surveillance of blaL1 from 105 ICU patients with clinically suspected multi-resistant
infections. The sequences of these blaL1 genes were conservative with only a few
sites mutated, and the strains had highly resistant to β-lactam antibiotics. The MLST
recovered that 22 strains belonged to seven different S. maltophilia sequence types (STs).
Furthermore, co-occurrence of blaL1 and blaL2 genes were detected in all of isolates.
Strikingly, S. maltophilia DCPS-01 was recovered to contain blaL1, blaL2, and blaNDM−1
genes, possessing an ability to hydrolyse all β-lactams antibiotics. Our data showed the
diversity types of S. maltophilia carrying blaL1 and co-occurrence of many resistant genes
in the clinical strains signal an ongoing and fast evolution of S. maltophilia resulting from
their wide spread in the respiratory infections, and therefore will be difﬁcult to control.
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INTRODUCTION
Stenotrophomonas maltophilia, commonly associated with res-
piratory infections in children and adults, is an emerging
Gram-negative MDRO (multi-drug-resistant organism) of global
signiﬁcance (Brooke, 2012). Currently, the incidence of S. mal-
tophilia nosocomial infection is increasing, particularly for the
immunocompromised (cancer, cystic ﬁbrosis, drug addicts, and
AIDS patients), dialysis patients, recipients of organ transplants,
in addition to the reported cases of community-acquired S. mal-
tophilia. The low outer membrane permeability of S. maltophilia
renders it inherently resistant to most antibiotics, whilst the pro-
duction of group 2e β-lactamase (L2) and group 3c β-lactamase
(L1) confers resistance to β-lactam containing antibiotics (Alonso
and Martínez, 1997). The blaL1 existed on a 200-kb plasmid,
encoding a broad-spectrum metallo-β-lactamase which hydrol-
yses carbapenems (Walsh et al., 1994; Avison et al., 2001), is
usually produced at higher levels (induced) that hydrolyzes almost
all known penicillins, cephalosporins, and carbapenems during
β-lactam challenge. The ease of acquisition and spread of this
antibiotic resistant gene of blaL1 in S. maltophilia emphasizes
the need for antibiotic susceptibility testing of clinical isolates.
At present, blaL1 has been identiﬁed in some clinical isolates of
S. maltophilia with important drug resistance against carbapen-
ems (Avison et al., 2001), so detection of blaL1 plays an important
role to indicate the infection of S. maltophilia in the clinical work
(Alonso and Martínez, 2000; AI-Jasser, 2006; Gould et al., 2006).
Recently, a number of molecular biology techniques have been
used to detect different strains of S. maltophilia (Nakamura et al.,
2010). PCR ampliﬁcation of the 16S rRNA gene was used to detect
S. maltophilia in blood samples of patients who are undergoing
chemotherapy for acute leukemia or myelodysplastic syndrome
(Nakamura et al., 2010). However, PCR requires specialized
high-cost instruments and consumables. In addition, Taq DNA
polymerase in PCR assays can be inactivated by inhibitors present
in crude biological samples but the large fragment of Bst DNA
polymerase (the large fragment of Bst DNA polymerase is part
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of Bacillus stearothermophilus DNA polymerase, it has 5′–3′ DNA
polymerase activity) in loop-mediated isothermal ampliﬁcation
(LAMP) assays is more resistant to inhibitors present in crude
biological samples (de Franchis et al., 1988; Kaneko et al., 2007).
Thus, another rapid, simple and cost effective assay is needed to
complement current PCR methods. The LAMP method which
was developed in 2000 relies on auto-cycling strand displace-
ment DNA synthesis which proceeds under isothermal conditions,
typically within 60 min, and in the presence of Bst DNA poly-
merase (Notomi et al., 2000; Song et al., 2005). In this study, we
develop this new method to detect the blaL1 of S. maltophilia. The
LAMP method has been shown to amplify target DNA with high-
speciﬁcity, and it is used widely in the clinical detection of bacteria
(Hara-Kudo et al., 2005; Ohtsuka et al., 2005), viruses (Okafuji
et al., 2005), parasites (Chen et al., 2011; Kong et al., 2012), and for
fetal sex identiﬁcation (Hirayama et al., 2006).
Data on the prevalence of blaL1 in S. maltophilia from ICU of
Chinese hospitals are lacking. The objective of the current study
is to develop a rapid, simple assay for S. maltophilia and to further
investigate the infection status and the species distribution of blaL1
in clinic. At ﬁrst, we designed ﬁve primer sets which each set targets
six or eight sequences on the blaL1. The speciﬁcity and sensitivity
of the primers for blaL1 was conﬁrmed, and the LAMP method
used for the detection of blaL1 in clinical samples. Then, basing on
this LAMP assays, dissemination and molecular characterization
of L1-producing S. maltophilia isolates was investigated at ICU
patients in three top hospitals (the hospitals that have large scale
and many patients) in Beijing, China.
MATERIALS AND METHODS
BACTERIAL ISOLATES, IDENTIFICATION, MLST TYPING, AND
ANTIMICROBIAL SUSCEPTIBILITY TESTING
A total of 37 bacterial strains were used in this study to develop the
LAMP assays, and their sources are listed in Table 1. S. maltophilia
K279a carrying blaL1 and blaL2 with the typical antimicrobial
resistance properties was used as the positive control. The other
species including common clinical infectious species and homol-
ogous species with S. maltophilia stored at our laboratory were
used for estimating the sensitivity and speciﬁcity of the LAMP
assay. 105 clinical nasopharyngeal swabs and sputum samples
were collected from ICU hospitalized patients with clinically sus-
pected multi-resistant infections in the 307 hospital, 302 hospital,
and 301 hospital in China, and species identiﬁcation was carried
out using an automated system (Phoenix and BD systems) and
matrix-assisted laser desorption ionization time-of-ﬂight mass
spectrometry (MALDI-TOF MS). 16S rDNA and blaL1 were val-
idated by PCR-based sequencing, and their sequence showed
100% (for 16S rDNA) and 98–100% (for blaL1) identity with the
sequences of previously reported genes, respectively. The allele
number for each gene was assigned on the basis of the informa-
tion in theMLSTdatabase1. A combination of the allelic sequences
of the seven genes yielded the allelic proﬁle. Antimicrobial suscep-
tibility testing was performed by microbroth dilution according
to the Clinical and Laboratory Standards Institute (CLSI, Clini-
cal and Laboratory Standards Institute Performance standards for
1http://pubmlst.org/smaltophilia/
antimicrobial susceptibility testing; Twentieth informational sup-
plement CLSI Document M100-S20, Wayne, PA, USA 2010.), and
Etest strips (bioMérieux) for carbapenems. The carbapenemase
activity of isolates was assessed by Etest MBLs.
The strains were screened for the presence of knownMBL genes
(blaVIM, blaIMP, blaSPM−1, blaGIM−1, blaSIM−1, blaAIM−1, and
blaNDM−1) by PCR with primers as reported previously (Patzer
et al., 2009). The strains were also screened for the presence of
other β-lactamase genes (blaCTX, blaCMY, etc.; Poirel et al., 2007).
ISOLATION OF GENOMIC DNA
The 37 bacterial strains and the 105 clinical samples were cultured
in brain heart infusion (BHI) broth at 37◦C according to a stan-
dard protocol. Chelex® 100 was used to extract total genomic
DNA (including plasmid DNA) from 5 ml overnight bacterial
cultures. Brieﬂy, 500 μl bacterial suspension was centrifuged at
10,000 × g for 2 min and the supernatant discarded. The pellet
was resuspended in 500 μl distilled water and 500 μl Chelex DNA
extraction buffer (25 mM NaOH, 10 mM Tris-HCl, 1% Triton X-
100, 1% NP-40, 0.1 mM EDTA, 2% Chelex-100) added. The cell
suspension was heated in boiling water for 10 min, held on ice for
5 min, and centrifuged at 14,000 × g for 2 min. The extracted
DNA was used as template in the LAMP and PCR reactions.
As for isolation of DNA from clinical sputum samples, DNA
was extracted directly from 200 μl clinical sputum samples with
the TIANamp Genomic DNA Kit (TIANGEN Biotech Co., Ltd.,
Beijing, China). The DNA was puriﬁed with the SV GEL and
PCR Clean-Up System (Promega Co., USA). The DNA concentra-
tionwas detectedusing the SpectrophotometerND-1000 (Thermo
Fisher Scientiﬁc, Inc., USA).
PRIMER DESIGN
A total of 20 blaL1 in the NCBI GenBank database (Gen-
Bank: HQ822273.1; EF126060.1; EF126061.1; AM743169.1;
AB294542.1; AJ251814.1; JF705927.1; JF705926.1; EF126051.1;
EF126054.1; EF126053.1; EF601224.1; AB294547.1; AB294545.1;
AJ291672.1; AF010282.1; AB194306.1; AJ289085.1; AJ289086.1;
AB194305.1) were compared, then the sequences of conserved
regions were chosen to design the primer sets. Primer Explorer
V4 software2 was used to design the outer forward primer (F3),
outer backward primer (B3), forward inner primer (FIP), back-
ward inner primer (BIP) and backward loop primer (loop B), used
to accelerate the ampliﬁcation reaction. Mergers of bases are used
to circumvent the mutational site (Table 2). The FIP and BIP
primers were linked by a four thymidine spacer (TTTT). Conven-
tional PCR was performed using primers labeled L1-23-F3 and
L1-23-B3. The primers were synthesized by Sangon Biotech Co.,
Ltd. (Shanghai, China).
LAMP REACTION
A 25 μl reaction volume was used for all LAMP reactions and
contained the following components (ﬁnal concentration): 20mM
Tris-HCl (pH 8.8), 10 mM KCl, 10 mM (NH4)2SO4, 0.1% Tween
20, 0.8 M betaine, 8 mM MgSO4, 1.4 mM each dNTP, and 8 U Bst
DNApolymerase. The amount of primer per reactionwas 40 pmol
2http://primerexplorer.jp/e/
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Table 1 | Bacterial strains used in the current study.
Species Source
Stenotrophomonas maltophilia-2 Clinical isolate
S. maltophilia-17 Clinical isolate
S. maltophilia-24 Clinical isolate
S. maltophilia-25 Clinical isolate
S. maltophilia-36 Clinical isolate
S. maltophilia-41 Clinical isolate
S. maltophilia-51 Clinical isolate
S. maltophilia-58 Clinical isolate
S. maltophilia-63 Clinical isolate
S. maltophilia-65 Clinical isolate
S. maltophilia-66 Clinical isolate
S. maltophilia-67 Clinical isolate
S. maltophilia -3859 Clinical isolate
S. maltophilia-4621 Clinical isolate
S. maltophilia-WJ2 Clinical isolate
S. maltophilia-K279a Our microorganism center
Acinetobacter baumannii B260 Our microorganism center
A. baumannii H18 Our microorganism center

















Neisseria meningitidis group B
CMCC29022
Our microorganism center
Salmonella aberdeen 9264 Our microorganism center
Salmonella enteritidis 50326-1 Our microorganism center
Salmonella paratyphi 86423 Our microorganism center
Shigella ﬂexneri 4536 Our microorganism center
Shigella sonnei 2531 Our microorganism center
Staphylococcus aureus 2740 Our microorganism center
Vibrio carchariae 5732 Our microorganism center
V. cholera 3802 Our microorganism center
V. parahaemolyticus 5474 Our microorganism center
Yersinia enterocolitica 1836 Our microorganism center
Y. pestis 2638 Our microorganism center
FIP and BIP, 20 pmol LB, 5 pmol F3 and B3. The appropriate
amount of DNA template was included in the reaction volume.
The LAMP assay proceeded in a reaction tube (Eiken Chemical
Co., Ltd., Tochigi, Japan) for 60 min at 65◦C.
DETECTION OF LAMP PRODUCTS
Two independent methods, based on either sample turbidity
or ﬂuorescence were used to detect LAMP products. Real-time
changes in turbidity were monitored by measuring the optical
density (λ650 nm) at 6 s intervals, for each LAMP reaction in a
Loopamp real-time turbidimeter (LA-320c; Eiken Chemical Co.,
Ltd.). The changes in turbidity arose from the presence of the
ampliﬁcation by-product Mg2P2O7 (a white precipitate).
The second method used direct visual inspection to assess color
changes in the presence of the ﬂuorescent metal ion indicator
calcein/Mn2+ complex. One microliter of calcein/Mn2+ complex
(Eiken Chemical Co., Ltd.) was added to 25μl LAMP reaction
volume prior to the commencement of the LAMP assay. On com-
pletion of the reaction a change in color from orange to green
indicated a positive reaction, whilst no color change indicated a
negative reaction. The color change was observed by the naked eye
under natural light or under UV light at 365 nm.
PCR DETECTION
A 25 μl reaction volume was used for all PCR reactions and
contained the following components: 12.5 μl PCR Taq Mas-
terMix (Tiangen Biotech Co., Ltd.), 9.5 μl double distilled
water, 1 μM L1-23F3 and L1-23B3 primers, and DNA tem-
plate. The oligonucleotide primers used for cloning blaL1 are
F: 5′-atgcgttctaccctgctcgccttcgcc-3′ and R: 5′-tcagcgggccccggcc
gtttccttggccag-3′. The PCR was carried out as follows: initial PCR
activation step, 94◦C for 2min; ampliﬁcation, 35 cycles of 94◦C for
30 s, 59◦C for 30 s, and 72◦C for 30 s; ﬁnal extension step, 72◦C for
10 min. The amplicons were puriﬁed using a PCR Puriﬁcation Kit
(TIANGEN Biotech Co., Ltd., Beijing, China) and sequenced by
Beijing AuGCT DNASYN Biotechnology Co., Ltd. The sequences
were compared with sequences in the GenBank database.
RESULTS
THE OPTIMAL PRIMER SETS FOR LAMP ASSAY
Five primer sets were detected in the same reaction condition using
real-time turbidimeter and their turbidity curves were draw at
650 nm according to the ampliﬁed results. The optimal primer
sets ampliﬁed the target sequence with the shortest time among
them was chosen for further investigation (see Table 2).
SENSITIVITY OF THE LAMP METHOD FOR blaL1 DETECTION
The sensitivity of the LAMP method for detecting blaL1 was eval-
uated using genomic DNA extracted from S. maltophilia K279a
(Wizard Genomic DNA puriﬁcation Kit), serially diluted 10-fold
from 379 ng/μl to 0.00379 pg/μl. As shown in Figure 2A, the
detection limit of the LAMP assay for blaL1 was 3.790 pg/μl.
Visual inspection of the color change, post-LAMP assay, and in the
presence of calcein/Mn2+ complex conﬁrmed reactions positive
(green) and negative (orange) for blaL1(Figure 2B). The results
from the twodetectionmethodswere in agreementwith sensitivity
for blaL1. PCR reactions on the serially diluted DNA using primers
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Table 2 | Primers used for the amplification of blaL1.
Primer Type Sequence (5’–3’)
L1-23F3 Forward outer CGGCATGCCACAGATGG
L1-23B3 Backward outer GCAGCACCGCCGTTTCT
L1-23FIP Forward inner TCAATCGCAGGTCCTGCGGTTTTCGGTCACCTGCTGGACAAC
L1-23BIP Backward inner CTY(C/T)AGCCATGCGCAY(T/C)GCS(C/G)GATTTTGCATTGGCCGCCACATG
L1-23LB Loop backward TCGCCGAGCTCAAGCGT
FIGURE 1 | Specificity of the LAMP method for blaL1 gene
detection. It has two parts, (A) is the graphic and (B) is the
photography of microtubes. The reaction proceeded at 65◦C for
65 min. Turbidity was monitored in the Loopamp real-time
turbidimeter and the OD(λ650nm) recorded at 6 s intervals. L1,
Brucella suis 3572; L2, Bacillus megatherium 4623; L3, Vibrio
carchariae 5732; L4, Acinetobacter baumannii B260; L5,
Corynebacterium diphtheriae CMCC38001; L6, Acinetobacter baumannii
H18; L7, Mycobacterium tuberculosis 8362; L8, Shigella sonnei 2531;
L9, Shigella ﬂexneri 4536; L10, Salmonella enteritidis 50326-1; L11,
Yersinia enterocolitica 1836; L12, Vibrio parahaemolyticus 5474; L13,
Salmonella paratyphi 86423; L14, Neisseria meningitidis group B
CMCC29022; L15, Enterotoxigenic E. coli 44824; L16, Beta hemolytic
Streptococcus group A CMCC32213; L17, Yersinia pestis 2638; L18,
Salmonella aberdeen 9264; L19, Vibrio cholera 3802; L20,
Staphylococcus aureus 2740; L21, Bordetella pertussis ATCC 18530;
L22, positive control (S. maltophilia -K279a); L23, negative control
(distilled water).
L1-23F3 and L1-23B3 were also conducted, and the detection limit
for blaL1 was established as 379 pg/μl (Figure 2C).
SPECIFICITY OF THE LAMP METHOD FOR blaL1 DETECTION
The speciﬁcity of the LAMP method for detecting blaL1 was evalu-
ated using S. maltophilia K279a with blaL1 as the positive control,
distilled water as the negative control, and 21 strains without
carrying blaL1 including common clinical infectious species and
homologous species with S. maltophilia as test subjects. As shown
in Figure 1A, turbidity increased only when S. maltophilia K279a
with blaL1 was used as template DNA in the LAMP assay. When
distilled water and the 21 remaining bacterial species were used
as template, no changes in turbidity were recorded. These results
suggest that the primers had good speciﬁcity for blaL1. In addition,
these results are consistent with those obtained using the ﬂuores-
cent indicator calcein/Mn2+ complex. Whereby, only the LAMP
assay with S. maltophilia K279a with blaL1 recorded a color change
from orange to green, indicative of a positive reaction (Figure 1B).
Whilst, all test samples negative for blaL1 and the negative control
remained orange, indicative of a negative reaction.
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FIGURE 2 | Comparison of the sensitivities for blaL1 gene detection by
LAMP and conventional PCR methods. Pure genomic DNA extracted from
S. maltophilia-K279a was diluted tenfold (379.0 ng/μl to 0.00379 pg/μl) and
the DNA assayed by LAMP (A,B) and PCR (C). (A)Turbidity was monitored
using the Loopamp real-time turbidimeter and the OD recorded at 650 nm, at
6 s intervals. (B) Visual inspection of the color change, post-LAMP assay, and
in the presence of calcein/Mn2+ complex. (C) PCR products were analyzed
by 2% agarose gel electrophoresis and stained with ethidium bromide. The
DNA marker is D2000 DNA Marker (Tiangen Biotech Co., Ltd.) The size is
about 179 bp.
DISSEMINATION OF L1-PRODUCING S. maltophilia IN CLINICAL
A total of 105 clinical sputum samples and nasopharyngeal swabs
were collected for LAMP-based surveillance of blaL1 from 105 ICU
patients with clinically suspected multi-resistant infections from
the department of Respiratory Diseases in three top hospitals. Ten
pairs of sputum samples and nasopharyngeal swabs from healthy
people were collected as controls.
All clinical samples were analyzed by LAMP and PCR simul-
taneously. Of the 105 patients samples, 22 were conﬁrmed to be
infected with S. maltophilia with blaL1 and 83 negative samples
by the LAMP assay (Figure 3), whilst the PCR assay detected
13 positive samples, and 92 negative samples. Then 22 strains
of S. maltophilia were isolated and identiﬁed from all of clinical
sputum samples and swabs samples, which the positive samples
were in accordence with those in LAMP assay. S. maltophilia with
blaL1 was positively identiﬁed 100% by LAMP and 86.7% by PCR,
respectively. None of the samples from healthy people was tested
as positive for blaL1. Thus, the results showed the LAMP assays
is more sensitive and the speciﬁc than PCR for diagnosis of S.
maltophilia in clinical practice.
The sequence analysis of the blaL1 genes from S. maltophilia
isolates conﬁrmed conservation with the nucleotide sequences of
reported genes or with only a few sites mutated. In the MLST
analysis of S. maltophilia, the results of seven housekeeper genes
recovered that 22 strains belonged to different sequence type (ST)
including ST4, ST8, ST 25, ST 28, ST29, or ST31, respectively.
To further characterize the 22 strains carrying blaL1 genes, the
susceptibility pattern was detected and clearly showed that all iso-
lates had highly resistant to β-lactam antibiotics. The isolates also
tested positive for MBLs in both the imipenem-EDTA double-disk
synergy test (DDST) and modiﬁed Hodge test (MHT).
Furthermore, PCR screening of the isolates were performed
for the known MBL genes including blaNDM−1, blaVIM, blaIMP,
blaSPM−1, blaGIM−1, blaSIM−1, blaAIM−1, and blaL2 (Patzer et al.,
2009). PCR yielded products of 22 isolates with expected sizes
for blaL1, and sequencing of these genes showed 100% identi-
ties with previously reported genes. It’s interesting to note that
the isolate named as S. maltophilia DCPS-01 contained L1 and
L2 β-lactamase genes with a novel blaNDM−1 which has attracted
wide attention because of its superior resistance to all β-lactam
antibiotics, which presented increased carbapenemase activity to
all β-lactams (MIC >128 μg/mL for imipenem and meropenem),
aminoglycosides and quinolones, and was only susceptible to
tigecycline and colistin.
Therefore, our data showed the diversity genotypic features
of S. maltophilia carrying blaL1 indicated wide spread in the
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FIGURE 3 | Loop-mediated isothermal amplification results for 15 S.
maltophilia strains positive for blaL1 isolated from 15 clinical samples.
(A)Turbidity was monitored using Loopamp, and the OD measured at 650 nm
every 6 s. (B) Visual inspection of calcein/Mn2+ complex associated color
changes post-LAMP assay. 1, S. maltophilia-2; 2, S. maltophilia-17; 3, S.
maltophilia-24; 4, S. maltophilia-25; 5, S. maltophilia-36; 6, S. maltophilia-41; 7,
S. maltophilia-51; 8, S. maltophilia-58; 9, S. maltophilia-63; 10, S.
maltophilia-65; 11, S. maltophilia-66; 12, S. maltophilia-67; 13, S.
maltophilia-3859; 14, S. maltophilia-4621; 15, S. maltophilia -WJ2; 16, positive
control (S. maltophilia-K279a); 17, negative control (distilled water).
respiratory infections. Importantly, the emergence of these pow-
erful co-occurring resistance mechanisms described here pro-
vides warning that future therapeutic options may be seriously
limited.
DISCUSSION
Stenotrophomonas maltophilia is a widespread environmental bac-
terium that has become a nosocomial pathogen of increasing
importance. It is currently the third most common nosocomial
non-fermenting bacteria, behind Pseudomonas aeruginosa and
Acinetobacter baumannii, and is associxated with crude mortality
rates ranging from 14 to 69% in patients with bacteraemias (Jang
et al., 1992; Victor et al., 1994). Of the 1661 antibiotic resistant
strains of S. maltophilia recovered from 14 hospitals across several
regions of China during 2010, the majority (97.5%) were isolated
from patients. Approximately 68.3% of strains were isolated from
patients ≥60 years of age, whilst only 4.8% were from patients
<18 years of age. Most (83.0%) isolates were recovered from spu-
tum and respiratory tract secretions (The data and information
from CHINET: CHINET 2010 surveillance of antibiotic resistance
in S. maltophilia in China). Within hospitals, the bacterium is
most often found in water sources, and can be a contaminant of
hospital equipment such as nebulizers and intravenous catheters.
From these sources, the organism can infect patients, resulting in
a wide spectrum of symptoms dependent upon the site of infec-
tion, though, most commonly, S. maltophilia causes bacteraemias
or respiratory tract infections (Denton and Kerr, 1998). β-Lactam
resistance is due to the expression of the β-lactamases L1, which
together hydrolyze the full range of β-lactamdrugs,with the excep-
tion of monobactams (Walsh et al., 1994). It is therefore necessary
to detect and monitor antibiotic resistance, persistence and spread
of S. maltophilia within the community and in health care settings.
Loop-mediated isothermal ampliﬁcation assays are generally
less time and labor intensive compared with traditional meth-
ods of pathogen detection, in part because the ampliﬁcation of
the target gene is performed at a constant temperature, and the
reaction times are usually less than an hour. To date, a method
for detecting S. maltophilia based on LAMP assays has not been
reported. In the current study, we designed primers speciﬁc for
the metallo-β-lactamase blaL1 for use in a LAMP assay to detect
S. maltophilia in clinical samples. Results from the speciﬁcity and
sensitivity analyses demonstrated that the LAMP method detected
genomic DNA at 3.79 pg/μl, and was speciﬁc for the β-lactamase
blaL1. In the speciﬁcity and sensitivity detection, we only use the
blaL1 of S. maltophilia K279a as the target gene, although many
other S.maltophilia strains do not have the same sequence of blaL1,
the most conserve regions of blaL1 were chosed to design the deci-
sive primers. In LAMP reaction, it is not true that all the primers
should combine with the target sequence. The decisive primers
are the FIP and BIP, if the FIP and BIP can combine with the
target sequence, the reaction is certain to occur, well, of course,
more novel experiments should bemade to ensure this conclusion.
Although the LAMP method has complex ampliﬁcation principle,
the assay is rapid, easy to operate, highly sensitive and speciﬁc, and
proceeds under isothermal conditions. We believe this assay would
be suitable for use in inspection and quarantine departments and
in health care units to test for S. maltophilia, and we anticipate
its routine use in hospital testing regimes, particularly for rapid
clinical testing.
A drawback of the LAMP method is the relatively high false-
positive rates; a consequence of the assay’s high sensitivity (Notomi
et al., 2000). Strict spatial separation of reagent preparation from
the testing area is necessary to avoid contamination. In the current
study, a sealing agent was applied to the reaction tube once the
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reaction mixture had been prepared, and its presence is useful in
preventing contamination.
In conclusion, we designed a detection method based on LAMP
for the speciﬁc, sensitive, rapid, and effective detection of the
metallo-β-lactamase blaL1 of S. maltophilia. We believe this tech-
nique would greatly beneﬁt hospitals and health units, and we
anticipate that LAMP will become the gold standard for the rapid
detection of pathogens in clinical samples. At the same time, this
report provides new insights into the mechanisms of drug resis-
tance andwarning that future therapeutic optionsmaybe seriously
limited.
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